ARCT-154 is also currently being studied in an ongoing pivotal trial in Vietnam, sponsored and funded by Arcturus’ collaborator Vinbiotech.
The study is evaluating Arcturus’ COVID vaccine candidates as both a primary vaccination series and as a booster following initial vaccination with Comirnaty®. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced new data and updates from clinical development programs for ARCT-154 and ARCT-165, its investigational, next-generation, self-amplifying mRNA vaccine candidates targeting variants of concern.ĪRCT-154 and ARCT-165 are being studied in a Phase 1/2 trial, sponsored by Arcturus, in U.S. SAN DIEGO, CA, USA I DecemI Arcturus Therapeutics Holdings Inc. Preliminary data from ongoing clinical booster study of ARCT-154 (5 mcg) shows a 50-fold increase in neutralizing antibody geometric mean concentration against SARS-CoV-2 using a validated pseudovirus microneutralization (MNT) assayĪdditional data shows activity against several variants of concern and variants of interest upon boosting with ARCT-154 (5 mcg) and ARCT-165 (5 mcg) in a surrogate virus neutralization (sVNT) assayĬompany to evaluate sera from ARCT-154 and ARCT-165 vaccinated participants for activity against the omicron variant initial data anticipated Q1 2022